Clinician-Administered PTSD Scale (CAPS-5)

Abstract

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) represents the internationally recognized gold standard for the structured clinical diagnostic assessment of Posttraumatic Stress Disorder (PTSD) in both clinical and investigative research settings. Developed by senior investigators at the National Center for PTSD (U.S. Department of Veterans Affairs), the instrument is a 30-item, clinician-rated structured diagnostic interview explicitly mapped onto the diagnostic architecture of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The assessment operationalizes the four core PTSD symptom clusters: Criterion B (Intrusive Symptoms; 5 items), Criterion C (Persistent Avoidance; 2 items), Criterion D (Negative Alterations in Cognitions and Mood; 7 items), and Criterion E (Alterations in Arousal and Reactivity; 6 items). In addition, the instrument incorporates dimensional and categorical evaluations of symptom onset and duration (Criterion F; 2 items), functional impairment and subjective distress (Criterion G; 3 items), clinician-rated global validity and symptom severity (3 items), and the DSM-5 Dissociative Subtype consisting of depersonalization and derealization (2 items).

Unlike prior iterations (e.g., CAPS-1 through CAPS-IV) that evaluated symptom frequency and intensity across distinct dimensional axes before algorithmic combination, the CAPS-5 streamlines clinical judgment into a single, standardized 5-point severity rating scale ranging from 0 (Absent) to 4 (Extreme / Incapacitating). A symptom is operationalized as categorically present at a threshold severity rating of 2 (Moderate / Threshold). Extensive psychometric validation studies across veteran, active-duty military, and diverse civilian trauma-exposed cohorts demonstrate outstanding psychometric properties, including high internal consistency (Cronbach’s α = .88–.95; McDonald’s ω = .90–.94), exceptional inter-rater reliability (intraclass correlation coefficients [ICCs] > .90; Cohen’s κ = .82–1.00), strong test-retest stability (r = .78–.88), and robust convergent validity with legacy instruments (such as the CAPS-IV, r = .83) and self-report measures including the PTSD Checklist for DSM-5 (PCL-5; r = .70–.85). Confirmatory factor analyses consistently substantiate both the four-factor DSM-5 structural model and expanded contemporary models such as the six-factor anhedonia and seven-factor hybrid models.

Keywords

Clinician-Administered PTSD Scale, CAPS-5, Posttraumatic Stress Disorder, DSM-5, structured clinical interview, psychometrics, construct validity, intrusive re-experiencing, trauma assessment, dissociative subtype, diagnostic reliability, National Center for PTSD

Authors

The Clinician-Administered PTSD Scale for DSM-5 was developed by a consortium of clinical psychometricians and research psychologists affiliated with the National Center for PTSD, United States Department of Veterans Affairs, and collaborating academic medical institutions:

• Frank W. Weathers, Ph.D. — Department of Psychology, Auburn University, Auburn, Alabama; Executive Research Consultant, National Center for PTSD.
• Dudley D. Blake, Ph.D. — Behavioral Science Division, National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts.
• Paula P. Schnurr, Ph.D. — Executive Director, National Center for PTSD; Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
• Danny G. Kaloupek, Ph.D. — Behavioral Science Division, National Center for PTSD, VA Boston Healthcare System; Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.
• Brian P. Marx, Ph.D. — Behavioral Science Division, National Center for PTSD, VA Boston Healthcare System; Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.
• Terence M. Keane, Ph.D. — Associate Chief of Staff for Research and Development, VA Boston Healthcare System; Director, Behavioral Science Division, National Center for PTSD; Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.

Correspondence regarding instrument administration, clinical training protocols, and licensing permissions is managed through the National Center for PTSD Instrument Request Portal.

Purpose

Posttraumatic Stress Disorder is a debilitating psychiatric condition that can develop following direct exposure to, witnessing of, or secondary confrontation with actual or threatened death, serious physical injury, or sexual violence. Given the profound clinical heterogeneity, high psychiatric comorbidity (e.g., major depressive disorder, substance use disorders, generalized anxiety disorder), and forensic or compensation-seeking contexts often surrounding trauma survivors, precise psychometric quantification of posttraumatic symptomatology is paramount. The Clinician-Administered PTSD Scale (CAPS-5) was engineered specifically to address the methodological limitations of self-report symptom inventories and unstructured clinical interviews, serving as the definitive criterion measurement tool for clinical diagnosis and empirical research.

Clinical Diagnostic Applications

In standard clinical practice, the CAPS-5 facilitates a rigorous, standardized diagnostic evaluation that systematically determines whether an individual meets full categorical criteria for PTSD according to the DSM-5. Unstructured interviews are inherently vulnerable to clinician confirmation bias, information variance, and variable thresholding. Conversely, patient self-report questionnaires often exhibit symptom overreporting due to distress amplification, reading comprehension disparities, or difficulty in delineating trauma-specific intrusions from non-specific rumination or generalized somatic distress. The CAPS-5 integrates structured inquiry, mandatory behavioral follow-up probes, and clinician guidance rules to ensure that endorsed symptoms are explicitly tied to the index traumatic event identified via Criterion A assessment (such as through the Life Events Checklist for DSM-5, LEC-5). It serves as the primary diagnostic adjudicator in specialized trauma clinics, psychiatric inpatient admissions, medical-legal evaluations, and Department of Veterans Affairs disability compensation assessments.

Research Applications and Clinical Trials

Within empirical psychiatric research, the CAPS-5 provides both dichotomous categorical diagnostic decisions (PTSD Present vs. Absent) and a continuous dimensional metric of total symptom severity (ranging from 0 to 80 across the 20 core DSM-5 symptom items). This dual capability makes it the standard primary outcome measure in psychopharmacological randomized controlled trials (evaluating, for instance, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or novel empathogens) and manualized evidence-based psychotherapies (such as Cognitive Processing Therapy [CPT], Prolonged Exposure [PE], and Eye Movement Desensitization and Reprocessing [EMDR]). Its continuous severity gradient allows researchers to track micro-level symptom fluctuations across treatment intervals, assess partial remission, quantify clinically meaningful change thresholds, and establish reliable indices of diagnostic loss.

Rationale for the DSM-5 Transition

The progression from the DSM-IV-TR to the DSM-5 involved profound reconceptualizations of PTSD. The disorder was removed from the Anxiety Disorders cluster and reclassified within a dedicated chapter: Trauma- and Stressor-Related Disorders. The historical three-factor model of PTSD (Re-experiencing, Avoidance/Numbing, and Hyperarousal) was revised into a four-factor architecture separating active behavioral avoidance from negative cognitive and affective alterations. Furthermore, several novel symptoms were introduced, including pervasive negative beliefs, persistent distorted blame, persistent negative affective states, and reckless or self-destructive behavior. The CAPS-5 was constructed to reflect these conceptual modifications directly, eliminating historical structural ambiguities and transitioning the measurement paradigm from distinct frequency-by-intensity matrices to a parsimonious, psychometrically optimized severity continuum.

Psychological Construct

The latent construct assessed by the CAPS-5 is Posttraumatic Stress Disorder as operationalized in the DSM-5. The interview captures an intricate constellation of affective, cognitive, physiological, and behavioral disturbances that manifest in the aftermath of severe psychological trauma. The scale encompasses several discrete yet interacting symptom domains and specifiers:

Criterion A: Trauma Exposure

Although assessed via collateral tools such as the LEC-5 prior to administering the core CAPS-5 interview, Criterion A is the fundamental gating requirement. The individual must have been exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence through direct experience, in-person witnessing, learning that the event occurred to a close family member or friend (violent or accidental), or experiencing repeated or extreme exposure to aversive details of traumatic events (e.g., first responders, forensic investigators).

Criterion B: Intrusion Symptoms (Items 1–5)

Intrusion symptoms capture the recurring, involuntary, and intrusive cognitive, sensory, and affective re-experiencing of the traumatic event. This dimension reflects a profound failure of emotional memory consolidation and contextual inhibition:

• B1 (Intrusive Memories): Involuntary, waking memories of the trauma that recur despite efforts to suppress them.
• B2 (Distressing Dreams): Recurrent distressing dreams whose manifest content or emotional tone is directly linked to the trauma.
• B3 (Dissociative Flashbacks): Dissociative reactions in which the person feels or acts as though the traumatic event were actively recurring, spanning a continuum from fleeting sensory illusions to complete loss of current environmental awareness.
• B4 (Cue-Reactivity Distress): Intense or prolonged psychological distress when exposed to internal or external reminders that resemble or symbolize an aspect of the traumatic event.
• B5 (Physiological Reactivity): Marked physiological arousal (e.g., tachycardia, diaphoresis, hyperventilation, tremor) triggered by trauma cues.

Criterion C: Persistent Avoidance (Items 6–7)

Criterion C evaluates purposeful behavioral and cognitive strategies deployed by the patient to circumvent exposure to internal or external trauma cues, maintained through negative reinforcement:

• C1 (Internal Avoidance): Deliberate efforts to suppress, avoid, or escape distressing memories, thoughts, or emotional/physical feelings associated with the trauma.
• C2 (External Avoidance): Behavioral avoidance of environmental reminders, including specific individuals, physical locations, conversations, sensory cues, objects, or contextual activities that trigger trauma recollections.

Criterion D: Negative Alterations in Cognitions and Mood (Items 8–14)

Criterion D reflects profound disruptions in semantic memory, belief systems, emotional processing, and social attachment that began or worsened after the trauma:

• D1 (Trauma-Related Amnesia): Inability to recall important aspects of the traumatic event, typically dissociative in nature and not attributable to traumatic brain injury, substance intoxication, or neurocognitive delirium.
• D2 (Negative Appraisals): Persistent and exaggerated negative beliefs or expectations about oneself, others, or the world (e.g., “I am permanently broken,” “No one can ever be trusted,” “The entire world is a catastrophic trap”).
• D3 (Distorted Blame): Persistent, distorted cognitions regarding the etiology or consequences of the traumatic event that lead the individual to inappropriately blame themselves or innocent external parties.
• D4 (Pervasive Negative Affect): Persistent, intense negative emotional states, explicitly encompassing fear, horror, anger, guilt, or shame.
• D5 (Diminished Interest / Anhedonia): Markedly diminished interest or participation in significant premorbid activities, hobbies, or occupational pursuits.
• D6 (Interpersonal Detachment): Subjective feelings of alienation, emotional detachment, or estrangement from other individuals, including immediate family.
• D7 (Restricted Positive Affect): Persistent psychical inability to experience authentic positive emotions, such as happiness, love, tenderness, or emotional warmth.

Criterion E: Alterations in Arousal and Reactivity (Items 15–20)

Criterion E assesses chronic neurobiological hyperarousal, deficits in threat detection modulation, and regulatory behavioral deficits:

• E1 (Irritability and Aggression): Irritable behavior and angry verbal or physical outbursts directed against people or inanimate objects with minimal or absent objective provocation.
• E2 (Reckless or Self-Destructive Behavior): Uninhibited risk-taking, dangerous driving, unsafe sexual behavior, self-injurious actions, or hazardous substance misuse.
• E3 (Hypervigilance): Chronic, state-independent scanning of the environment for ambiguous threat signals, manifested by strategic positioning (e.g., facing room entrances) and somatic tension.
• E4 (Exaggerated Startle Response): Heightened, abnormal motor and autonomic reactivity to unexpected acoustic, visual, or physical stimuli.
• E5 (Concentration Impairment): Subjective and objective deficits in sustained attention, working memory, and mental focus during daily tasks.
• E6 (Sleep Disturbance): Severe difficulties initiating or maintaining restorative sleep, or highly restless, fragmented nocturnal architecture.

Criteria F and G, Specifiers, and Global Indices

Criterion F benchmarks symptom chronological onset (acute vs. delayed expression ≥ 6 months) and persistence (> 1 month duration). Criterion G measures subjective distress alongside objective functional impairment across social, familial, and occupational spheres. Finally, items 29 and 30 evaluate the Dissociative Subtype, capturing persistent or recurrent experiences of depersonalization (feeling detached from one’s mental processes or physical body) and derealization (unreality or dreamlike detachment from one’s surroundings).

Theoretical Framework

The conceptual and operational architecture of the CAPS-5 is rooted in classical and contemporary cognitive-behavioral, emotional processing, and neurobiological paradigms of traumatic stress.

Mowrer’s Two-Factor Learning Theory

Early behavioral formulations of PTSD relied heavily on Mowrer’s Two-Factor Theory. In the initial phase, classical conditioning pairs a traumatic unconditioned stimulus (UCS; e.g., severe physical assault) with neutral contextual stimuli (conditioned stimuli, CS; e.g., ambient lighting, odors, spatial configurations), eliciting an intense conditioned fear response (CR). In the second phase, operant conditioning solidifies active avoidance and cognitive escape behaviors (Criterion C). Because retreating from trauma-related stimuli reduces immediate autonomic arousal, avoidance is reinforced via negative reinforcement, paradoxically preventing the natural extinction of conditioned fear associations.

Emotional Processing Theory (EPT)

Developed by Edna Foa and Michael Kozak, Emotional Processing Theory posits that traumatic events generate extensive, pathological fear structures in long-term memory. These fear networks comprise cognitive representations of feared stimuli (e.g., screams, gunfire), behavioral and physiological fear responses (e.g., racing heart, fleeing), and interpretive meaning elements (e.g., “I am powerless,” “Death is imminent”). In patients who develop PTSD, these structures are characterized by excessively high associative strength, erratic stimulus-response linkages, and overgeneralized interpretive meanings. Intrusion symptoms (Criterion B) reflect the involuntary activation of this pathological network by cues sharing partial similarity with the original trauma. Successful recovery requires activating the fear structure and integrating corrective information that contradicts erroneous threat appraisals, a mechanism hindered by persistent avoidance (Criterion C).

Cognitive Model of Persistent PTSD

The cognitive model formulated by Anke Ehlers and David M. Clark posits that persistent PTSD occurs when individuals process the traumatic event and its sequelae in a manner that produces a sense of ongoing, current serious threat. This subjective sense of threat is fueled by two interconnected mechanisms: excessively negative appraisals of the trauma or its aftermath (e.g., interpreting traumatic amnesia as evidence of permanent brain damage; Criterion D2, D3), and characteristic disturbances in autobiographical memory. Trauma memories are poorly integrated into the individual’s broader autobiographical context, lacking coherent temporal and spatial tags. Consequently, when involuntary memories are cued, they lack “time-tagging,” producing the terrifying subjective experience that the event is recurring in the present (Criterion B3).

Dual Representation Theory

Chris Brewin’s Dual Representation Theory differentiates between two primary types of memory representations: Verbally Accessible Memories (VAM) and Situationally Accessible Memories (SAM). VAM representations are encoded through hippocampal-cortical networks and can be voluntarily retrieved and integrated into autobiographical discourse. In contrast, under conditions of extreme neurobiological stress and adrenergic surges during trauma, hippocampal processing is compromised while amygdala-dependent perceptual processing remains heightened. This leads to the formation of fragmented, sensory-bound SAM representations. SAMs cannot be accessed intentionally; rather, they are automatically triggered by perceptual matches in the environment, manifesting clinically as vivid intrusive flashbacks, nightmares, and autonomic arousal (Criteria B1–B5).

Neurobiological and Neurocircuitry Models

The structural composition of the CAPS-5 directly maps onto established fronto-limbic dysregulation models of PTSD. Extensive functional neuroimaging literature highlights hyperresponsiveness within the amygdala and dorsal anterior cingulate cortex (dACC), paired with structural and functional hypoactivation within the ventromedial prefrontal cortex (vmPFC) and anterior hippocampus. The vmPFC is responsible for top-down inhibitory control over amygdaloid fear centers; its hypofunction results in a failure to inhibit fear responses to non-threatening trauma reminders, driving the hypervigilance, autonomic arousal, and startle responses captured in Criterion E.

Validity

The psychometric validity of the CAPS-5 has been evaluated across military veterans, active combat personnel, emergency first responders, civilian sexual assault survivors, and community clinical samples. The instrument consistently exhibits exceptional construct, convergent, discriminant, and diagnostic criterion validity.

Convergent and Concurrent Validity

Convergent validity evaluates the extent to which CAPS-5 scores align with established measures of PTSD and related posttraumatic psychopathology. In the seminal psychometric validation investigation by Weathers et al. (2018), the CAPS-5 demonstrated high convergent validity with the legacy gold standard, the CAPS-IV, yielding a strong correlation coefficient of r = .83. When compared against validated self-report instruments assessing DSM-5 PTSD symptoms, the CAPS-5 continuous severity score consistently achieves strong correlations with the PTSD Checklist for DSM-5 (PCL-5), with bivariate coefficients typically ranging between r = .70 and r = .85 across veteran and civilian validation cohorts. Correlations with other structured clinical interviews, including the Structured Clinical Interview for DSM-5 (SCID-5) PTSD module and the Mini-International Neuropsychiatric Interview (M.I.N.I.), routinely exceed r = .75.

Discriminant Validity

Discriminant validity assesses the capacity of the CAPS-5 to differentiate PTSD from related, often comorbid, internalizing and externalizing psychiatric conditions. While CAPS-5 severity scores correlate moderately with self-report and clinician-rated measures of depression (e.g., Patient Health Questionnaire-9 [PHQ-9], r ≈ .50–.65; Beck Depression Inventory-II [BDI-II], r ≈ .55–.68) and generalized anxiety (e.g., Generalized Anxiety Disorder 7-item scale [GAD-7], r ≈ .45–.60), these correlations are significantly lower than its correlations with dedicated PTSD instruments. Furthermore, structural equation modeling confirms that the latent factor of PTSD captured by CAPS-5 remains empirically distinct from general negative affectivity, somatization, and antisocial personality traits, establishing that the instrument does not merely index non-specific psychological demoralization.

Criterion and Diagnostic Accuracy

The diagnostic utility of the CAPS-5 has been established using receiver operating characteristic (ROC) analyses. Using consensus multidisciplinary diagnostic panels and structured cross-evaluations as reference standards, the CAPS-5 demonstrates an Area Under the Curve (AUC) exceeding .90 (typically .92–.96). Operating under the standard DSM-5 scoring algorithm (where a symptom is counted toward diagnostic criteria if rated ≥ 2, and Criterion A, B, C, D, E, F, and G thresholds are met), the instrument displays balanced sensitivity (ranging from .81 to .89) and specificity (ranging from .83 to .92). For clinical trials requiring high diagnostic certainty, researchers frequently employ higher continuous cut scores (e.g., a total severity score of 25–30) to maximize positive predictive value and eliminate subthreshold cases.

Reliability

The CAPS-5 possesses exceptional reliability across multiple measurement parameters, including internal consistency, inter-rater agreement, and temporal stability over repeated test administrations.

Internal Consistency

Internal consistency reflects the degree of interrelatedness among the scale items. Across diverse epidemiological, clinical, and veteran validation studies, the CAPS-5 exhibits high internal consistency for its 20 core symptom items. Standard Cronbach’s alpha coefficients for the total continuous severity score routinely fall between α = .88 and α = .95. When evaluated using modern composite reliability estimators that do not assume tau-equivalence, McDonald’s omega values regularly span ω = .90 to .94. Individual symptom cluster internal consistencies remain robust despite varying item counts:

• Criterion B (Intrusion): α = .82–.88
• Criterion C (Avoidance): α = .74–.82 (notably strong given its 2-item structure)
• Criterion D (Negative Alterations in Cognition and Mood): α = .84–.90
• Criterion E (Arousal and Reactivity): α = .79–.86

Inter-Rater Reliability

Because the CAPS-5 is a semi-structured clinician interview requiring subjective operational ratings, inter-rater reliability is critical. In formal psychometric trials where independent raters simultaneously observed live or audio/video-recorded interviews, intraclass correlation coefficients (ICCs) for the continuous severity summary score ranged from .91 to .98, demonstrating strong measurement concordance across clinical raters. For categorical diagnostic decisions (PTSD Present vs. Absent), inter-rater agreement yields Cohen’s kappa values ranging from κ = .82 to 1.00, reflecting near-perfect consensus. Item-level intraclass correlations across all 30 individual items demonstrate strong rater agreement, with median item-level ICCs exceeding .80.

Test-Retest Stability

Temporal stability across brief test-retest intervals (typically 1 to 2 weeks, minimizing genuine therapeutic change or clinical deterioration) is high. Pearson product-moment correlation coefficients for the continuous severity total score range between r = .78 and r = .88. Categorical test-retest diagnostic agreement yields kappa coefficients between κ = .70 and κ = .83, confirming that the measurement tool remains stable over time in the absence of targeted interventions.

Factor Analysis

The structural dimensionality of the CAPS-5 has been investigated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA). These analyses examine whether empirical observations align with the diagnostic organization codified in the DSM-5 or alternative structural models proposed in the quantitative trauma psychopathology literature.

The DSM-5 Four-Factor Model

The foundational structural baseline for the CAPS-5 is the DSM-5 four-factor model, specifying four correlated first-order latent dimensions corresponding to the diagnostic criteria: Intrusion (items B1–B5), Avoidance (items C1–C2), Negative Alterations in Cognitions and Mood (items D1–D7), and Alterations in Arousal and Reactivity (items E1–E6). In CFA investigations conducted across large military and civilian samples (e.g., Weathers et al., 2018; Bovin et al., 2016), this four-factor model exhibits adequate to good fit:

• Comparative Fit Index (CFI) ≥ .91–.94
• Tucker-Lewis Index (TLI) ≥ .90–.93
• Root Mean Square Error of Approximation (RMSEA) ≤ .05–.07
• Standardized Root Mean Square Residual (SRMR) ≤ .04–.06

Standardized factor loadings across all 20 core symptom items are strong and statistically significant (p < .001), generally spanning from .55 to .86, confirming that each item reliably reflects its parent diagnostic construct.

Alternative Structural Models

Despite the adequacy of the DSM-5 model, empirical structural investigations in psychotraumatology frequently identify superior statistical fit in alternative multi-factor formulations that disaggregate broad emotional and hyperarousal clusters:

• The Six-Factor Anhedonia Model: Separates Criterion D into a distinct Cognitive/Blame factor and an Anhedonia/Emotional Numbing factor, while dividing Criterion E into Dysphoric Arousal and Anxious Arousal. CFA investigations consistently demonstrate superior fit indices for this model over the DSM-5 four-factor model (CFI > .95, TLI > .94, RMSEA < .05).
• The Seven-Factor Hybrid Model: Further disaggregates symptoms into seven correlated factors: Intrusion, Avoidance, Negative Affect, Anhedonia, Externalizing Behavior, Anxious Arousal, and Dysphoric Arousal. In veteran and trauma-exposed community samples, this model often provides the best statistical fit, isolating distinct neurobiological pathways associated with specific symptom clusters.

Despite the statistical superiority of these six- and seven-factor configurations in CFA literature, the CAPS-5 remains primarily scored and interpreted via the official four-factor DSM-5 system to preserve diagnostic clarity and regulatory compliance.

Instrument / Measurement Tool

• Test Type: Clinician-administered semi-structured diagnostic interview.
• Target Population: Adults (aged 18 and older) exposed to Criterion A traumatic events. (A specialized child/adolescent variant, the CAPS-CA-5, is utilized for youth aged 7 to 17).
• Administration Format: In-person or synchronous telehealth clinical interview conducted by a trained mental health professional or qualified psychometrician.
• Time Required: Approximately 45 to 60 minutes for the full 30-item evaluation (may extend up to 90 minutes in complex cases involving multiple trauma histories and severe dissociative or psychiatric comorbidity).
• Item Count: 30 items total, comprising:
  • 20 core DSM-5 PTSD symptom items (Items 1–20)
  • 2 symptom onset and duration items (Items 21–22)
  • 3 subjective distress and functional impairment items (Items 23–25)
  • 3 clinician global evaluation items (Items 26–28)
  • 2 dissociative subtype items (Items 29–30)
• Response Format: Standardized 5-point clinician severity rating scale:
  • 0 = Absent: The respondent denied the problem or the respondent’s report doesn’t fit the DSM-5 symptom criterion.
  • 1 = Mild / subthreshold: The respondent described a problem that is consistent with the symptom criterion but isn’t severe enough to be considered clinically significant.
  • 2 = Moderate / threshold: The respondent described a clinically significant problem. The problem satisfies the DSM-5 symptom criterion and is a problem of at least moderate severity.
  • 3 = Severe / markedly elevated: The respondent described a problem that is well above operational threshold. The problem is difficult to manage and at least occasionally pronounced.
  • 4 = Extreme / incapacitating: The respondent described a dramatic symptom, physically exhausting or mentally debilitating, obvious to even a casual observer.
• Diagnostic Scoring Rules:
  • Symptom Threshold Rule: An individual symptom is scored as categorically Present if it receives a clinician severity rating of 2 (Moderate / threshold) or higher.
  • Categorical PTSD Diagnosis: Requires confirmation of Criterion A exposure (typically via the Life Events Checklist [LEC-5]) plus:
    • At least 1 Criterion B symptom rated ≥ 2 (Items 1–5)
    • At least 1 Criterion C symptom rated ≥ 2 (Items 6–7)
    • At least 2 Criterion D symptoms rated ≥ 2 (Items 8–14)
    • At least 2 Criterion E symptoms rated ≥ 2 (Items 15–20)
    • Criterion F satisfied: Total symptom duration > 1 month (Item 22)
    • Criterion G satisfied: Clinically significant subjective distress or impairment rated ≥ 2 on at least one functional domain (Items 23–25)
  • Continuous Severity Score: Calculated by summing the severity ratings across the 20 core symptom items (Items 1–20). The total continuous score ranges from 0 to 80, providing a granular index of overall PTSD symptom burden.
  • Dissociative Subtype Specifier: Endorsed if the diagnostic criteria for PTSD are met and either Item 29 (Depersonalization) or Item 30 (Derealization) receives a severity rating of ≥ 2.

Permissions & Fee and Test Year

The Clinician-Administered PTSD Scale for DSM-5 was officially published in 2015 following the release of the DSM-5. The CAPS-5 is the intellectual property of the National Center for PTSD, United States Department of Veterans Affairs. It is classified as an open-access public domain research and clinical instrument, meaning it is made available free of charge to qualified healthcare professionals, clinical researchers, and academic institutions.

Although the assessment is distributed at no monetary cost, prospective administrators must submit a formal request via the online portal on the National Center for PTSD website: https://www.ptsd.va.gov/professional/assessment/ncptsd-instrument-request-form.asp. Commercial redistribution, inclusion in fee-for-service software systems, or modification of interview items and standardized probes without written authorization from the National Center for PTSD is prohibited. Because the CAPS-5 is a complex clinical diagnostic interview, formal training in structured psychodiagnostic assessment and trauma psychopathology is strongly recommended to ensure scoring reliability.

References

• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425596
• Bovin, M. J., Marx, B. P., Weathers, F. W., Gallagher, M. W., Rodriguez, P., Schnurr, P. P., & Keane, T. M. (2016). Psychometric properties of the PTSD Checklist for DSM-5 (PCL-5) in veterans. Psychological Assessment, 28(11), 1379–1391. https://doi.org/10.1037/pas0000254
• Brewin, C. R. (2001). A cognitive neuroscience account of posttraumatic stress disorder and its treatment. Behaviour Research and Therapy, 39(4), 373–393. https://doi.org/10.1016/S0005-7967(00)00087-5
• Ehlers, A., & Clark, D. M. (2000). A cognitive model of posttraumatic stress disorder. Behaviour Research and Therapy, 38(4), 319–345. https://doi.org/10.1016/S0005-7967(99)00123-0
• Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99(1), 20–35. https://doi.org/10.1037/0033-2909.99.1.20
• Marx, B. P., Lee, D. J., Norman, S. B., Bovin, M. J., Sloan, D. M., Weathers, F. W., Keane, T. M., & Schnurr, P. P. (2022). Reliable and clinically significant change in the Clinician-Administered PTSD Scale for DSM-5 and PTSD Checklist for DSM-5 among male veterans. Psychological Assessment, 34(2), 197–203. https://doi.org/10.1037/pas0001098
• Weathers, F. W., Blake, D. D., Schnurr, P. P., Kaloupek, D. G., Marx, B. P., & Keane, T. M. (2015). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) – Past Month. National Center for PTSD. https://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp
• Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychological Assessment, 30(3), 383–395. https://doi.org/10.1037/pas0000486
• Weathers, F. W., Keane, T. M., & Davidson, J. R. T. (2001). Clinician-Administered PTSD Scale: A review of the first ten years of research. Depression and Anxiety, 13(3), 132–156. https://doi.org/10.1002/da.1029

13. Items of the Scale (Questionnaire)